Skip to content

INVESTOR RELATIONS

genXone company is active in the biotechnology industry and offers nucleic acid (DNA and RNA) sequencing services based on the innovative nanopore sequencing technology, Next-Generation Sequencing (NGS), also known as third-generation sequencing. 

The company is the first in Poland to be accredited and licensed for commercial use of the nanopore sequencing technology developed by Oxford Nanopore Technologies (ONT). Based on the access to ONT technology, the company creates its own, new solutions in the form of laboratory protocols as well as bioinformatics tools, scripts and algorithms, enabling the use of nanopore sequencing in many areas of science and business, including in genetic diagnostics, food industry, veterinary medicine and agriculture. The experienced team of genXone, which consists of specialists in the field of molecular genetics and bioinformatics, works on modern solutions. The activity of genXone is complemented by the Molecular Diagnostics Laboratory, which conducts research using the Real-Time PCR method, including the detection and quantification of pathogens in various human systems.

LISTING

On the 25th of August 2020, genXone S.A was welcomed to the floor of the NewConnect market.

From 2003, she’s worked at Diagnostyka S.A., where recently has held the position of Deputy Sales Director. Until 2019, she was the President of the Management Boards of the largest Polish network of non-public pathomorphological institutes: Diagnostyka Consilio and Histamed Diagnostyka Consilio. In 2004-2009 she was the President of the Academy of Modern Diagnostics Foundation. She is a doctor of biological sciences. She graduated from the Jagiellonian University.